Efficacy of Vitamin D3 Supplementation in Elevating Circulating 25(OH)D Concentration in Individuals With Chronic Spinal Cord Injury (VitD-SCI): Evidence From a Randomized, Double-Blind, Placebo-Controlled Trial.

Individuals with spinal cord injury (SCI) are at increased risk for insufficient 25(OH)D levels and associated adverse health outcomes, highlighting the need for vitamin D supplementation. However, the optimal dosing strategy for vitamin D supplementation in this population remains unclear. To evalu...

Descripción completa

Detalles Bibliográficos
Publicado en:Topics in Spinal Cord Injury Rehabilitation Vol. 31; no. 4; pp. 61 - 74
Autores principales: Hertig-Godeschalk, Anneke, Brinkhof, Martin W. G., Perret, Claudio, Scheel-Sailer, Anke, Flueck, Joelle L.
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: KnowledgeWorks Global, Ltd Fall2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=189391920&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 189391920
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10820744
        0OF
      jtl: Topics in Spinal Cord Injury Rehabilitation
      issn: 10820744
      maglogo: N
    pubinfo:
      dt: Fall2025
      vid: 31
      iid: 4
      pid: 81084
      pub: KnowledgeWorks Global, Ltd
      place: Richmond, Virginia
    artinfo:
      ui:
        189391920
        189391920
        189391920
        10.46292/sci24-00077
        189391920
      ppf: 61
      ppct: 13
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Efficacy of Vitamin D3 Supplementation in Elevating Circulating 25(OH)D Concentration in Individuals With Chronic Spinal Cord Injury (VitD-SCI): Evidence From a Randomized, Double-Blind, Placebo-Controlled Trial.
      aug:
        au:
          Hertig-Godeschalk, Anneke
          Brinkhof, Martin W. G.
          Perret, Claudio
          Scheel-Sailer, Anke
          Flueck, Joelle L.
        affil: Swiss Paraplegic Research, Nottwil, Switzerland
      sug:
        subj:
          Cholecalciferol Administration and Dosage
          Vitamin D Blood
          Spinal Cord Injuries Drug Therapy
          Chronic Disease Drug Therapy
          Drug Efficacy Evaluation
          Patient Safety Evaluation
          Human
          Randomized Controlled Trials
          Double-Blind Studies
          Male
          Female
          Adult
          Middle Age
          Random Assignment
          Placebos Administration and Dosage
          Drug Tolerance
          Body Mass Index
          Seasons
          Hospitals, Private
          Switzerland
          Questionnaires
          Biological Assay
          Descriptive Statistics
          Pearson's Correlation Coefficient
          Chi Square Test
          One-Way Analysis of Variance
          Repeated Measures
          Data Analysis Software
          Two-Tailed Test
          Funding Source
          Dose-Response Relationship, Drug
          Models, Statistical
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Male
          Female
      ab: Individuals with spinal cord injury (SCI) are at increased risk for insufficient 25(OH)D levels and associated adverse health outcomes, highlighting the need for vitamin D supplementation. However, the optimal dosing strategy for vitamin D supplementation in this population remains unclear. To evaluate the efficacy of medium-dose (MD) and high-dose (HD) vitamin D3 supplementation in raising 25(OH)D levels above the sufficiency threshold of 75 nmol/L in individuals with SCI. A 12-month randomized, double-blind, placebo-controlled, superiority clinical trial was conducted in 42 individuals living with SCI for at least 3 years and who had insufficient 25(OH)D levels at baseline. Participants (7 female, 35 male; age 48 ± 10 years; 32 with paraplegia, 10 with tetraplegia) were randomly assigned to the placebo, MD intervention (24,000 IU D3 once every 4 weeks), or HD intervention (24,000 IU D3 once every 2 weeks) group. Baseline 25(OH)D levels (43 ± 16 nmol/L) did not differ between intervention groups (P =.8). Supplementation was well tolerated, and 25(OH)D levels remained well below the excess threshold. A dose-response effect on 25(OH)D levels was observed [F(2, 40) = 8.21, P <.001]. In the HD group, 46% of the participants reached sufficient levels. Participants having an incomplete lesion, higher baseline 25(OH)D levels, lower body mass index, supplementation during summer, autumn, or winter, or higher sun scores were more likely to reach sufficient 25(OH)D levels. Vitamin D3 supplementation effectively increased 25(OH)D concentration to sufficient levels in participants with specific characteristics. Higher supplementation doses are needed to successfully increase 25(OH)D levels in all individuals with chronic SCI.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N